Valuation: Photocure ASA

Market Cap 1.51B 157M 138M 128M 118M 221M 15.02B 224M 1.52B 595M 7.42B 588M 575M 25.64B P/E 2026 *
16.8x
P/E 2027 * 35.3x
Enterprise Value 1.31B 136M 119M 111M 102M 191M 13.01B 194M 1.32B 515M 6.43B 509M 498M 22.21B EV / Sales 2026 *
1.99x
EV / Sales 2027 * 1.94x
Free-Float
94.52%
Yield 2026 *
-
Yield 2027 * -
1 day-2.75%
Current month-2.75%
1 month-2.75%
3 months-14.99%
6 months-14.14%
Current year-14.14%
1 month 6.01
Extreme 6.01
6.01
Current year 6.01
Extreme 6.01
7.39
1 year 5.58
Extreme 5.58
7.39
3 years 4.32
Extreme 4.32
7.39
5 years 4.21
Extreme 4.21
15.87
10 years 3
Extreme 3
17.57
Manager TitleAgeSince
Chief Executive Officer - 01/11/2018
Chief Tech/Sci/R&D Officer - 01/08/2021
Human Resources Officer - 01/02/2021
Director TitleAgeSince
Director/Board Member - 01/01/2022
Chairman - 27/09/2023
Director/Board Member - 23/05/2024
Change 5-day change 1-year change 3-year change Capi.($)
-2.75%0.00% - - 156M
+0.15%+4.44%+48.23%+163.28% 1,067B
+0.97%+6.88%+60.00%+53.12% 635B
-0.94%+1.40%+36.28%+72.60% 458B
+1.41%+7.75%+38.93%+32.88% 347B
+1.28%+2.82%+38.42%+43.21% 295B
+1.72%+2.33%+19.31%+20.79% 262B
+1.84%-1.03%-27.78%-38.45% 216B
+0.06%+3.32%+24.88%+59.40% 203B
+0.94%-2.02%+15.47%+70.59% 161B
Average +0.74%+1.33%+28.19%+53.05% 404.83B
Weighted average by Cap. +0.83%+1.95%+37.77%+78.45%

Financials

2026 *2027 *
Net sales 660M 68.26M 60.01M 55.86M 51.3M 96.33M 6.55B 97.6M 664M 259M 3.23B 256M 251M 11.17B 665M 68.78M 60.46M 56.28M 51.69M 97.06M 6.6B 98.34M 669M 261M 3.26B 258M 253M 11.26B
Net income 91.33M 9.45M 8.31M 7.73M 7.1M 13.34M 906M 13.51M 91.93M 35.9M 448M 35.48M 34.71M 1.55B 43.33M 4.48M 3.94M 3.67M 3.37M 6.33M 430M 6.41M 43.62M 17.03M 212M 16.83M 16.47M 734M
Net Debt -203M -20.97M -18.44M -17.16M -15.76M -29.59M -2.01B -29.99M -204M -79.67M -993M -78.72M -77.03M -3.43B -221M -22.9M -20.13M -18.74M -17.21M -32.32M -2.2B -32.75M -223M -87.01M -1.08B -85.98M -84.12M -3.75B
Logo Photocure ASA
Photocure ASA is a Norway-based company active in the pharmaceutical industry. The Company is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
Employees
100
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
56.10NOK
Average target price
84.00NOK
Spread / Average Target
+49.73%

Quarterly revenue - Rate of surprise